These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 34861473)

  • 1. A computer-aided drug design approach to discover tumour suppressor p53 protein activators for colorectal cancer therapy.
    Patrício RPS; Videira PA; Pereira F
    Bioorg Med Chem; 2022 Jan; 53():116530. PubMed ID: 34861473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In Silico HCT116 Human Colon Cancer Cell-Based Models En Route to the Discovery of Lead-Like Anticancer Drugs.
    Cruz S; Gomes SE; Borralho PM; Rodrigues CMP; Gaudêncio SP; Pereira F
    Biomolecules; 2018 Jul; 8(3):. PubMed ID: 30018273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rational drug design for anti-cancer chemotherapy: multi-target QSAR models for the in silico discovery of anti-colorectal cancer agents.
    Speck-Planche A; Kleandrova VV; Luan F; Cordeiro MN
    Bioorg Med Chem; 2012 Aug; 20(15):4848-55. PubMed ID: 22750007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of Novel EGFR Inhibitors for the Targeted Therapy of Colorectal Cancer Using Pharmacophore Modelling, Docking, Molecular Dynamic Simulation and Biological Activity Prediction.
    Krishnan K A; Valavi SG; Joy A
    Anticancer Agents Med Chem; 2024; 24(4):263-279. PubMed ID: 38173208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthetic antiprotozoal thiazolide drug induced apoptosis in colorectal cancer cells: implications of IL-6/JAK2/STAT3 and p53/caspases-dependent signaling pathways based on molecular docking and in vitro study.
    Tantawy MA; El-Sherbeeny NA; Helmi N; Alazragi R; Salem N; Elaidy SM
    Mol Cell Biochem; 2020 Jun; 469(1-2):143-157. PubMed ID: 32356241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ruthenium-Containing Linear Helicates and Mesocates with Tuneable p53-Selective Cytotoxicity in Colorectal Cancer Cells.
    Allison SJ; Cooke D; Davidson FS; Elliott PIP; Faulkner RA; Griffiths HBS; Harper OJ; Hussain O; Owen-Lynch PJ; Phillips RM; Rice CR; Shepherd SL; Wheelhouse RT
    Angew Chem Int Ed Engl; 2018 Jul; 57(31):9799-9804. PubMed ID: 29863754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytotoxic 1,2,3-Triazoles as Potential Leads Targeting the S100A2-p53 Complex: Synthesis and Cytotoxicity.
    Sun J; Baker JR; Russell CC; Cossar PJ; Ngoc Thuy Pham H; Sakoff JA; Scarlett CJ; McCluskey A
    ChemMedChem; 2021 Sep; 16(18):2864-2881. PubMed ID: 34047450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proposing novel MDM2 inhibitors: Combined physics-driven high-throughput virtual screening and in vitro studies.
    Aydin G; Paksoy MN; Orhan MD; Avsar T; Yurtsever M; Durdagi S
    Chem Biol Drug Des; 2020 Jul; 96(1):684-700. PubMed ID: 32691963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of novel FUT8 inhibitors with promising affinity and in vivo efficacy for colorectal cancer therapy.
    Lv Y; Zhang Z; Wang M; Wang Y; Chen M; Jia J; Guo Y; Wang K; Li Z; Wang W; Li H
    Bioorg Chem; 2024 Aug; 149():107492. PubMed ID: 38820939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Diarylpentanoid with Potential Activation of the p53 Pathway: Combination of in silico Screening Studies, Synthesis, and Biological Activity Evaluation.
    Moreira J; Almeida J; Loureiro JB; Ramos H; Palmeira A; Pinto MM; Saraiva L; Cidade H
    ChemMedChem; 2021 Oct; 16(19):2969-2981. PubMed ID: 34170069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In silico and in vitro screening for potential anticancer candidates targeting GPR120.
    Pal A; Curtin JF; Kinsella GK
    Bioorg Med Chem Lett; 2021 Jan; 31():127672. PubMed ID: 33161126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the S100A2-p53 Interaction with a Series of 3,5-Bis(trifluoromethyl)benzene Sulfonamides: Synthesis and Cytotoxicity.
    Sun J; Ambrus JI; Russell CC; Baker JR; Cossar PJ; Pirinen MJ; Sakoff JA; Scarlett CJ; McCluskey A
    ChemMedChem; 2021 Sep; 16(18):2851-2863. PubMed ID: 34047071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, and evaluation of novel coumarin-dithiocarbamate derivatives (IDs) as anti-colorectal cancer agents.
    Zhu H; Ying S; Zhou B; Hu X; Liang X; Li W; Wang D; Jin H; Pan Y
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):593-604. PubMed ID: 33557648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
    El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
    Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Alkoxy Chain Length and 1-Hydroxy Group on Anticolorectal Cancer Activity of 2-Bromoalkoxyanthraquinones.
    Mekzali NW; Chee CW; Abdullah I; Lee YK; Rashid NN; Lee VS; Othman R; Hashim NM; Chee CF
    Med Chem; 2023; 19(9):897-905. PubMed ID: 37046198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Potential Anticancer Potency of Kolaviron on Colorectal Adenocarcinoma (Caco-2) Cells.
    Althagafi HA
    Anticancer Agents Med Chem; 2024; 24(15):1097-1108. PubMed ID: 38835121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In Vitro and In Silico Study of Analogs of Plant Product Plastoquinone to Be Effective in Colorectal Cancer Treatment.
    Ciftci H; Sever B; Ocak F; Bayrak N; Yıldız M; Yıldırım H; DeMirci H; Tateishi H; Otsuka M; Fujita M; TuYuN AF
    Molecules; 2022 Jan; 27(3):. PubMed ID: 35163957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative validated molecular modeling of p53-HDM2 inhibitors as antiproliferative agents.
    Mondal C; Halder AK; Adhikari N; Saha A; Saha KD; Gayen S; Jha T
    Eur J Med Chem; 2015 Jan; 90():860-75. PubMed ID: 25535952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and biological evaluation of novel pyrrolidone-based derivatives as potent p53-MDM2 inhibitors.
    Si D; Luo H; Zhang X; Yang K; Wen H; Li W; Liu J
    Bioorg Chem; 2021 Oct; 115():105268. PubMed ID: 34426149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potency and Selectivity Optimization of Tryptophanol-Derived Oxazoloisoindolinones: Novel p53 Activators in Human Colorectal Cancer.
    Barcherini V; Almeida J; Lopes EA; Wang M; Magalhães E Silva D; Mori M; Wang S; Saraiva L; Santos MMM
    ChemMedChem; 2021 Jan; 16(1):250-258. PubMed ID: 32737944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.